I follow TTG, but don't own it. They are the no. 2 co. in the reconditioned human tissue space behind LIFC (which I also follow, have owned, made a considerable amount of money, and highly recommend as a long-term hold).
TTG is a good play in this space. They produce collagen based tissue repair and bone matrix repair products for reconstructive surgery. The announcement that they will enter into the breast recon market is a direct response to LIFC's launch of Alloderm (their flagship product) in the breast recon space about a year ago. Alloderm has gained a big chunk of market share since that launch, helping LIFC to book 40% YOY revenue gains for at least the last 5-6 quarters.
TTG looks like LIFC about 4 years ago. They are now profitable, have a good distribution network (albeit through Bard rather than an internal network which cuts into profitability) and they too are growing at a healthy clip.
Be aware, LIFC has applied for and received a 510K approval for Strattice, a porcine equivalent to Alloderm. This is very important for two reasons. First, the profit margins on acquiring and prepping pig dermis for implantation is MUCH cheaper, and second, the industry generally frowns on using the scarce human skin resource (acquired by both co.'s from a network of tissue banks) for cosmetic products, limiting both LIFC's and TTG's human dermis products to repair and recon surgical procedures.
Strattice is designed to meet the need for breast augmentation market, which could be considerable.
aj
